
Retinitis Pigmentosa- Pipeline Insight, 2025
Description
DelveInsight’s, “Retinitis Pigmentosa- Pipeline Insight, 2025” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Retinitis Pigmentosa: Overview
Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. RP is a genetic disease that people are born with. Symptoms usually start in childhood, and most people eventually lose most of their sight. There’s no cure for RP. But vision aids and rehabilitation (training) programs can help people with RP make the most of their vision.
Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP also causes loss of side (peripheral) vision — so have trouble seeing things out of the corners of the eyes. Over time, field of vision narrows until only have some central vision (also called tunnel vision). Some people with RP lose their vision more quickly than others. Eventually, most people with RP lose their side vision and their central vision. Other symptoms of RP also include sensitivity to bright light and loss of color vision. Most of the time, RP is caused by changes in genes that control cells in the retina. These changed genes are passed down from parents to children. RP is linked to many different genes and can be inherited in different ways. If have RP, can talk with doctor or a specialist called a genetic counselor to learn more about risk of passing RP to children. Sometimes RP happens as part of other genetic conditions, like Usher syndrome. Usher syndrome causes both vision and hearing loss.
RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Other tests for RP include: Optical coherence tomography (OCT), Genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision.
Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa. The other ways to manage RP include: Using low vision aids and assistive devices. There are a range of magnifiers and technology that can identify things or people that the wearer points to, using sunglasses and other methods to avoid exposure to too much light. Light may make RP worse, treating associated conditions, such as cystoid macular edema (CME), which may happen with RP. CME refers to collections of fluid in the middle of retina, treating cataracts, which happens when the lens of eyes becomes cloudy, with surgery to remove them.
""Retinitis Pigmentosa- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided which includes the disease overview and Retinitis Pigmentosa treatment guidelines. The assessment part of the report embraces, in depth Retinitis Pigmentosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Retinitis Pigmentosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Retinitis Pigmentosa Emerging Drugs
Further product details are provided in the report……..
Retinitis Pigmentosa: Therapeutic Assessment
This segment of the report provides insights about the different Retinitis Pigmentosa drugs segregated based on following parameters that define the scope of the report, such as:
Retinitis Pigmentosa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Retinitis Pigmentosa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinitis Pigmentosa drugs.
Retinitis Pigmentosa Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Retinitis Pigmentosa: Overview
Retinitis pigmentosa (RP) is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. RP is a genetic disease that people are born with. Symptoms usually start in childhood, and most people eventually lose most of their sight. There’s no cure for RP. But vision aids and rehabilitation (training) programs can help people with RP make the most of their vision.
Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP also causes loss of side (peripheral) vision — so have trouble seeing things out of the corners of the eyes. Over time, field of vision narrows until only have some central vision (also called tunnel vision). Some people with RP lose their vision more quickly than others. Eventually, most people with RP lose their side vision and their central vision. Other symptoms of RP also include sensitivity to bright light and loss of color vision. Most of the time, RP is caused by changes in genes that control cells in the retina. These changed genes are passed down from parents to children. RP is linked to many different genes and can be inherited in different ways. If have RP, can talk with doctor or a specialist called a genetic counselor to learn more about risk of passing RP to children. Sometimes RP happens as part of other genetic conditions, like Usher syndrome. Usher syndrome causes both vision and hearing loss.
RP is diagnosed by electroretinography (ERG), visual field testing, and retinal imaging, fundus auto-fluorescence (FAF) and genetic testing. Other tests for RP include: Optical coherence tomography (OCT), Genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores the vision.
Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery etc. Gene therapy based treatments are under research focus for the treatment of Retinitis pigmentosa. The other ways to manage RP include: Using low vision aids and assistive devices. There are a range of magnifiers and technology that can identify things or people that the wearer points to, using sunglasses and other methods to avoid exposure to too much light. Light may make RP worse, treating associated conditions, such as cystoid macular edema (CME), which may happen with RP. CME refers to collections of fluid in the middle of retina, treating cataracts, which happens when the lens of eyes becomes cloudy, with surgery to remove them.
""Retinitis Pigmentosa- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided which includes the disease overview and Retinitis Pigmentosa treatment guidelines. The assessment part of the report embraces, in depth Retinitis Pigmentosa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Retinitis Pigmentosa R&D. The therapies under development are focused on novel approaches to treat/improve Retinitis Pigmentosa.
This segment of the Retinitis Pigmentosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Retinitis Pigmentosa Emerging Drugs
- Botaretigene sparoparvovec : MeiraGTx
- ADX-2191: Aldeyra Therapeutics, Inc.
- SPVN-06 : SparingVision
- FT-002: Frontera Therapeutics
Further product details are provided in the report……..
Retinitis Pigmentosa: Therapeutic Assessment
This segment of the report provides insights about the different Retinitis Pigmentosa drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Retinitis Pigmentosa
- There are approx. 40+ key companies which are developing the therapies for Retinitis Pigmentosa. The companies which have their Retinitis Pigmentosa drug candidates in the most advanced stage, i.e. phase III include, MeiraGTx
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Retinitis Pigmentosa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Retinitis Pigmentosa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinitis Pigmentosa drugs.
Retinitis Pigmentosa Report Insights
- Retinitis Pigmentosa Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Retinitis Pigmentosa drugs?
- How many Retinitis Pigmentosa drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinitis Pigmentosa?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinitis Pigmentosa therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Retinitis Pigmentosa and their status?
- What are the key designations that have been granted to the emerging drugs?
- MeiraGTx
- Aldeyra Therapeutics, Inc.
- SparingVision
- Frontera Therapeutics
- ProQR Therapeutics
- Bionic Sight
- RetroSense Therapeutics
- Dompe Farmaceutici
- Endogena Therapeutics
- Nacuity Pharmaceuticals
- Kiora Pharmaceuticals
- jCyte
- Ocugen
- Neurotech USA
- Nanoscope Therapeutics
- Botaretigene sparoparvovec
- ADX-2191
- SPVN-06
- FT-002
- Ultevursen
- BS 01
- RST-001
- Cenegermin
- EA-2353
- NPI-001
- KIO-301
- Retinal stem cell therapy
- OCU400
- NT-501
- MCO-010
Table of Contents
150 Pages
- Introduction
- Executive Summary
- Retinitis Pigmentosa: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Retinitis Pigmentosa– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Botaretigene sparoparvovec : MeiraGTx
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ADX-2191: Aldeyra Therapeutics, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- SPVN-06 : SparingVision
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Retinitis Pigmentosa Key Companies
- Retinitis Pigmentosa Key Products
- Retinitis Pigmentosa- Unmet Needs
- Retinitis Pigmentosa- Market Drivers and Barriers
- Retinitis Pigmentosa- Future Perspectives and Conclusion
- Retinitis Pigmentosa Analyst Views
- Retinitis Pigmentosa Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.